RESEARCH ARTICLE

Betulinic Acid-Azaprostanoid Hybrids: Synthesis and Pharmacological Evaluation as Anti-inflammatory Agents

Tatyana S. Khlebnicova[1,*], Yuri A. Piven[1], Fedor A. Lakhvich[1], Iryna V. Sorokina[2], Tatiana S. Frolova[2], Dmitry S. Baev[2] and Tatyana G. Tolstikova[2]

[1]*Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Acad. Kuprevicha Street 5/2, 220141, Minsk, Republic of Belarus;* [2]*N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 9 prosp. Acad. Lavrentieva, 630090, Novosibirsk, Russian Federation*

Abstract: ***Background:*** Prevention and treatment of chronic inflammatory diseases require effective and low-toxic medicines. Molecular hybridization is an effective strategy to enhance the biological activity of new compounds. Triterpenoid scaffolds are in the focus of attention owing to their anti-inflammatory, antiviral, antiproliferative, and immunomodulatory activities. Heteroprostanoids have different pleiotropic effects in acute and chronic inflammatory processes.

Objective: The study aimed to develop structurally new and low toxic anti-inflammatory agents *via* hybridization of betulinic acid with azaprostanoic acids.

Methods: A series of betulinic acid-azaprostanoid hybrids was synthesized. The synthetic pathway included the transformation of betulin *via* Jones' oxidation into betulonic acid, reductive amination of the latter and coupling obtained by 3β-amino-3-deoxybetulinic acid with the 7- or 13-azaprostanoic acids and their homo analogues. The hybrids **1-9** were investigated *in vivo* on histamine-, formalin- and concanavalin A-induced mouse paw edema models and two models of pain - the acetic acid-induced abdominal writhing and the hot-plate test. The hybrids were *in vitro* evaluated for cytotoxic activity on cancer (MCF7, U-87 MG) and non-cancer humane cell lines.

Results: In the immunogenic inflammation model, the substances showed a pronounced anti-inflammatory effect, which was comparable to that of indomethacin. In the models of the exudative inflammation, none of the compounds displayed a statistically significant effect. The hybrids produced weak or moderate analgesic effects. All the agents revealed low cytotoxicity on human immortalized fibroblasts and cancer cell lines compared with 3β-amino-3-deoxybetulinic acid and doxorubicin.

Conclusion: The results indicate that the principal anti-inflammatory effect of hybrids is substantially provided with the triterpenoid scaffold and in some cases with the azaprostanoid scaffold, but the latter makes a significant contribution to reducing the toxicity of hybrids. Hybrid **1** is of interest as a potent low toxic agent against immune-mediated inflammation.

*Address correspondence to this author at the Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Acad. Kuprevicha Street 5/2, 220141, Minsk, Republic of Belarus; Tel/Fax: +375-17-267-87-61; E-mail: khlebnicova@iboch.by

1. INTRODUCTION

Inflammation is a pivotal protective mechanism of host defense against an injury, wounds or infection. However, the persistent inflammation generates an excessive production of pro-inflammatory molecules and reactive species which could be the pathogenic factors initiating numerous chronic diseases, such as arthritis, atherosclerosis, diabetes and even cancer [1]. Many trials for finding new effective anti-inflammatory agents are being conducted [2]. Plant-derived substances are a valuable source of potent anti-inflammatory pharmacons [3], which have been used for structural modification by medicinal chemistry [4]. Triterpene scaffolds are in the focus of attention owing to their anti-inflammatory, antimicrobial, antiviral, antiproliferative, hepatoprotective and immunomodulatory activities [5-7]. The anti-inflammatory effect of pentacyclic triterpenoids is based on the inhibition of 5-LOX, iNOS, COX-2 and nuclear factor-kB (NF-kB) activities [8]. Betulinic acid (BA) is a naturally occurring pentacyclic triterpenoid, safe and non-toxic at doses up to 500 mg/kg body weight in mice [9]. BA is reported to have anti-inflammatory and immunomodulatory activities in numerous experimental models, including sepsis [10-13]. BA decreases pro-inflammatory mediators NO and PGE_2 in LPS-stimulated RAW 264.7 macrophages *via* the inhibition of inducible iNOS and COX-2. It also suppresses NF-κB pathway by blocking the phosphorylation of IκB-α [14]. The BA anti-inflammatory effect is mediated by the macrophages' induction and modulation of the immune response [8, 14].

The prostaglandins (PGs) are increased in inflamed tissue and usually thought to have pro-inflammatory effects such as: dolor (pain), calor (heat), rubor (redness) and tumor (swelling) [15]. Although the pro-inflammatory effects are well documented, the evidence that PGs could resolve inflammation was found. Cyclopentenone prostaglandins have been shown to possess anti-inflammatory activity [16, 17], which is revealed through the activation of peroxisome proliferator-activated receptor-g [18, 19] or through the direct inhibition and modification of the IKKβ subunit of IKK in NF-κB pathway [20]. Heteroprostanoids not only have anti-inflammatory, but also different

pleiotropic effects [21]. Thus, 7- and 13-azaprostanoids and their homo analogues [22], synthesized on the base of 2-acylcycloalkane-1,3-diones, exhibit anti-ulcerative, anti-arrhythmic and anti-ischemic activities [23, 24]. Molecular hybridization is an effective strategy to enhance the biological activity of new molecules [25, 26]. Keeping in view the fact that triterpenoids and azaprostanoids have different targets of anti-inflammatory effect, we supposed their hybridization could improve the pharmacological activities of the compounds.

In our continuing search for bioactive hybrid compounds [27-29], we present in the article the synthesis and *in vivo* investigation of anti-inflammatory and analgesic effects of nine betulinic acid-azaprostanoid hybrids including hybrids with 7-azaprostanoids **1-6** and hybrids with 13-azaprostanoids **7-9** (Fig. **1**). Furthermore, we evaluated the influence of azaprostanoid fragment on the cytotoxicity of a triterpenoid hybrid. To our knowledge, this is the first time report where 7- and 13-azaprostanoids were conjugated with the lupane skeleton.

2. MATERIALS AND METHODS

2.1. Chemistry

^{1}H and ^{13}C NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (500 MHz for ^{1}H, 125 MHz for ^{13}C). Chemical shift values are given in δ (ppm) relative to the residual solvent signals for δ_H 7.26 ppm and δ_C 77.16 ppm (CDCl$_3$), and for δ_H 2.04 ppm and δ_C 20.00 ppm (CD$_3$COOD). Melting points were measured on a Boetius apparatus and are uncorrected. High-resolution mass spectra (HRMS) were recorded on a 6550 iFunnel Q-TOF LC/MS (Agilent Technologies) micro mass spectrometer by electrospray ionization (ESI). The elemental analyses were performed on a Eurovector EA3000 CHNS-O analyzer. Follow-up of the reactions and evaluation of the purity of the compounds were performed by thin layer chromatography (TLC) on Silica gel (60 Å medium pore diameter) on TLC Al foils with a fluorescent indicator 254 nm (Sigma-Aldrich). Chemicals were purchased from Sigma-Aldrich or Acros Organics and used as received. Solvents were dried and freshly distilled according to the common practice.

Fig. (1). New synthesized and bioevaluated hybirds.

2.1.1. General Procedure for the Synthesis of Target Compounds 1-9

To a solution of azaprostanoic acids **11-19** (1 mmol) in methylene chloride (30 ml), *N,N'*-dicyclohexylcarbodiimide (160 mg, 1 mmol) was added. After stirring for 2 hr at room temperature, 3β-amino-3-deoxybetulinic acid (**10**) (460 mg, 1 mmol) and 4-dimethylaminopyridine (10 mg) were added to the mixture. After stirring for 16 hr, the precipitate was filtered and the filtrate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography with petroleum-ethyl acetate as an eluent to give the corresponding hybrids **1-9**.

2.1.1.1. 3-Deoxy-3β-((6-(2-heptanoyl-3-oxocyclopent-1-en-1-yl)amino)hexanamido))betulinic Acid (1)

Yield 55%; White solid; mp 123-127°C; ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.71-2.27 (m, 43H, CH, CH$_2$, CH$_3$), 0.71 (s, 3H, CH$_3$), 0.79 (s, 3H, CH$_3$), 0.83 (s, 3H, CH$_3$), 0.91 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.37-2.47 (m, 2H,

CH$_2$), 2.63-2.65 (m, 2H, CH$_2$), 2.88 (t, *J* = 7.5 Hz, 2H, CH$_2$), 3.00 (td, *J* = 10.7, 4.8 Hz, 1H, H-19), 3.35 (q, *J* = 6.7 Hz, 2H, CH$_2$), 3.64 (ddd, *J* = 14.2, 10.0, 4.5 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.71 (brs, 1H, H-29), 5.43 (d, *J* = 9.9 Hz, 1H, NH), 10.38 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 14.8, 16.2, 16.2, 16.6, 18.6, 19.4, 20.9, 22.7, 24.2, 24.3, 25.4, 25.6, 25.8, 26.5, 28.5, 29.3, 29.5, 29.8, 30.4, 30.7, 31.9, 32.3, 33.6, 34.3, 36.9, 37.2, 37.9, 38.5, 39.2, 40.6, 40.7, 42.5, 43.9, 47.1, 49.3, 50.5, 56.0, 56.4, 56.5, 109.8, 110.3, 150.6, 172.3, 181.3, 181.8, 200.0, 200.4. HR-MS (ESI): m/z calcd for C$_{48}$H$_{76}$N$_2$NaO$_5$ [M+Na]$^+$ 783.5652; found 783.5623.

2.1.1.2. 3-Deoxy-3β-((6-(2-heptanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanamido))betulinic Acid (2)

Yield 60%; White solid; mp 138-142°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.72-2.27 (m, 45H, CH, CH$_2$, CH$_3$), 0.72 (s, 3H, CH$_3$), 0.79 (s, 3H, CH$_3$), 0.84 (s, 3H, CH$_3$), 0.91 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.39 (t, *J* = 6.3

Hz, 2H, CH$_2$), 2.57 (t, *J* = 6.1 Hz, 2H, CH$_2$), 2.93 (t, *J* = 7.6 Hz, 2H, CH$_2$), 2.97-3.03 (m, 1H, H-19), 3.31 (q, *J* = 6.4 Hz, 2H, CH$_2$), 3.64 (td, *J* = 11.1 Hz, 10.0 Hz, 4.2 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.39 (d, *J* = 9.3 Hz, 1H), 12.57 (t, *J* = 5.2 Hz, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) *δ*: 14.2, 14.8, 16.2, 16.6, 18.7, 19.4, 19.9, 20.9, 22.8, 25.4, 25.6, 25.8, 26.6, 27.2, 28.6, 29.1, 29.4, 29.8, 30.7, 32.0, 32.3, 34.3, 36.9, 37.2, 37.9, 38.5, 38.6, 39.2, 40.7, 42.5, 43.5, 43.9, 47.1, 49.4, 50.5, 56.1, 56.5, 56.6, 108.8, 109.8, 150.6, 172.3, 173.0, 181.4, 195.0, 204.4. HR-MS (ESI): m/z calcd for C$_{49}$H$_{78}$N$_2$NaO$_5$ [M+Na]$^+$ 797.5808; found 797.5839.

2.1.1.3. 3-Deoxy-3β-((6-((2-heptanoyl-5,5-dimethyl-3-oxocyclohex-1-en-1-yl)amino)hexanamido)) betulinic Acid (3)

Yield 65%; White solid; mp 158-162°C. ^{1}H NMR (500 MHz, CDCl$_3$) *δ*: 0.72-2.25 (m, 43H, CH, CH$_2$, CH$_3$), 0.73 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.84 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.05 (s, 6H, 2CH$_3$), 1.68 (s, 3H, CH$_3$), 2.29 (s, 2H, CH$_2$), 2.41 (s, 2H, CH$_2$), 2.93-3.03 (m, 3H, H-19, CH$_2$), 3.32 (q, *J* = 6.3 Hz, 2H, CH$_2$), 3.65 (ddd, *J* = 14.1 Hz, 9.6 Hz, 4.2 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.37 (d, 1H, *J* = 10.1 Hz, NH), 12.70 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) *δ*: 14.3, 14.8, 16.2, 16.6, 18.7, 19.5, 20.9, 22.8, 25.4, 25.6, 25.9, 26.6, 28.5, 28.6, 29.2, 29.5, 29.8, 30.7, 32.0, 32.3, 34.3, 36.9, 37.2, 37.9, 38.5, 39.3, 40.6, 40.8, 42.6, 43.6, 43.9, 47.1, 49.4, 50.5, 52.1, 56.1, 56.5, 56.6, 107.6, 109.8, 150.6, 172.1, 172.3, 181.2, 194.5, 204.5. HR-MS (ESI): m/z calcd for C$_{51}$H$_{82}$N$_2$NaO$_5$ [M+Na]$^+$ 825.6121; found 825.6150.

2.1.1.4. 3-Deoxy-3β-((6-(2-octanoyl-3-oxocyclopent-1-en-1-yl)amino)hexanamido))betulinic Acid (4)

Yield 54%; White solid; mp 191-194°C. ^{1}H NMR (500 MHz, CDCl$_3$) *δ*: 0.72-2.28 (m, 45H, CH, CH$_2$, CH$_3$), 0.72 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.84 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.97 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.44-2.47 (m, 2H, CH$_2$), 2.65-2.67 (m, 2H, CH$_2$), 2.88 (td, *J* = 7.4, 2.1 Hz, m, 2H, CH$_2$), 3.01 (td, *J* = 10.8, 4.8 Hz, 1H, H-19), 3.36 (q, *J* = 6.8 Hz, 2H, CH$_2$), 3.65 (ddd, *J* = 14.3 Hz, 10.1 Hz, 4.4 Hz, 1H, H-3), 4.60

(brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.56 (d, *J* = 9.4 Hz, 1H, NH), 10.41 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) *δ*: 14.3, 14.8, 16.2, 16.3, 16.7, 18.7, 19.5, 20.9, 22.8, 24.3, 24.4, 25.5, 25.6, 25.8, 26.5, 28.6, 29.4, 29.5, 29.6, 29.8, 30.7, 31.9, 32.3, 33.6, 34.3, 36.8, 37.2, 37.3, 37.9, 38.6, 39.3, 40.7, 40.8, 42.6, 44.0, 47.1, 49.4, 50.5, 56.1, 56.5, 56.7, 109.8, 110.4, 150.6, 172.4, 181.2, 182.0, 200.0, 200.4. HR-MS (ESI): m/z calcd for C$_{49}$H$_{78}$N$_2$NaO$_5$ [M+Na]$^+$ 797.5808; found 797.5830.

2.1.1.5. 3-Deoxy-3β-((6-(2-octanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanamido))betulinic Acid (5)

Yield 59%; White solid; mp 131-135°C. ^{1}H NMR (500 MHz, CDCl$_3$) *δ*: ^{1}H NMR (500 MHz, CDCl$_3$) *δ*: 0.67-2.28 (m, 47H, CH, CH$_2$, CH$_3$), 0.73 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.84 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.39 (t, *J* = 6.0 Hz, 2H), 2.57 (t, *J* = 5.7 Hz, 2H), 2.93 (t, *J* = 7.7 Hz, 2H, CH$_2$), 2.97-3.03 (m, 1H, H-19), 3.32 (q, *J* = 6.5 Hz, 2H, CH$_2$), 3.64 (ddd, *J* = 14.1, 10.1, 4.4 Hz, 1H, H-3), 4.60 (brs, 1H, H-29), 4.73 (brs, 1H, H-29), 5.35 (d, *J* = 9.9 Hz, 1H, NH), 12.58 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) *δ*: 14.3, 14.8, 16.2, 16.6, 18.7, 19.5, 19.9, 20.9, 22.8, 25.4, 25.5, 25.6, 25.9, 26.6, 27.2, 28.6, 29.1, 29.4, 29.7, 29.8, 30.7, 32.0, 32.3, 34.4, 36.9, 37.2, 37.9, 38.5, 39.3, 40.8, 42.6, 43.5, 43.9, 47.1, 49.4, 50.6, 56.1, 56.5, 56.6, 108.8, 109.8, 150.6, 172.3, 173.1, 181.1, 195.0, 204.5. HR-MS (ESI): m/z calcd for C$_{50}$H$_{80}$N$_2$NaO$_5$ [M+Na]$^+$ 811.5965; found 811.5984.

2.1.1.6. 3-Deoxy-3β-((6-(5,5-dimethyl-2-octanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanamido)) betulinic Acid (6)

Yield 62%; White solid; mp 146-149°C. ^{1}H NMR (500 MHz, CDCl$_3$) *δ*: 0.64-2.25 (m, 45H, CH, CH$_2$, CH$_3$), 0.73 (s, 3H, CH$_3$), 0.79 (s, 3H, CH$_3$), 0.84 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.05 (s, 6H, 2CH$_3$), 1.68 (s, 3H, CH$_3$), 2.26 (s, 2H, CH$_2$), 2.41 (s, 2H, CH$_2$), 2.93-3.03 (m, 3H, CH$_2$, H-19), 3.31 (q, 2H, CH$_2$), 3.65 (ddd, *J* = 12.1, 9.8, 4.3 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.34 (d, *J* = 9.8 Hz, 1H, NH), 12.68 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) *δ*: 14.3, 14.8, 16.2, 16.6, 18.7, 19.5, 20.9, 22.8, 25.4, 25.5, 25.6, 28.5, 28.6, 29.3, 29.4,

29.7, 29.8, 30.7, 30.8, 32.0, 32.3, 34.4, 37.0, 37.2, 37.9, 38.5, 39.3, 40.6, 40.8, 42.6, 43.5, 43.9, 47.1, 49.4, 50.6, 52.2, 56.1, 56.5, 56.6, 107.7, 109.8, 150.6, 172.0, 172.3, 181.2, 194.5, 204.0. HR-MS (ESI): m/z calcd for $C_{52}H_{84}N_2NaO_5$ [M+Na]$^+$ 839.6278; found 839.6309.

2.1.1.7. *3-Deoxy-3β-((7-(2-heptylamino-5-oxocyclopent-1-enyl)-7-oxoheptanamido))betulinic Acid (7)*

Yield 65%; White solid; mp 130-133°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.73-2.28 (m, 45H, CH, CH$_2$), 0.73 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.85 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.41-2.43 (m, 2H, CH$_2$), 2.64-2.66 (m, 2H, CH$_2$), 2.83-3.03 (m, 3H, H-19, CH$_2$), 3.34 (q, *J* = 6.8 Hz, 2H, CH$_2$), 3.64 (ddd, *J*=12.2, 9.9, 4.4 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.54 (d, *J* = 9.9 Hz, 1H, NH), 10.36 (t, *J* = 6.3 Hz, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 14.8, 16.2, 16.6, 18.7, 19.5, 20.9, 22.7, 23.9. 24.2, 25.6, 25.8, 25.9, 26.9, 28.5, 28.9, 29.0, 29.8, 30.7, 31.7, 32.3, 33.7, 34.4, 37.1, 37.2, 37.9, 38.5, 39.3, 40.3, 40.8, 42.6, 44.3, 47.1, 49.4, 50.6, 56.1, 56.4, 56.5, 109.8, 110.3, 150.6, 173.0, 181.1, 181.8, 199.9, 200.1. HRMS (ESI): m/z calcd for $C_{49}H_{78}N_2NaO_5$ [M+Na]$^+$ 797.5808; found 797.5831.

2.1.1.8. *3-Deoxy-3β-((7-(2-heptylamino-6-oxocyclohex-1-enyl)-7-oxoheptanamido))betulinic Acid (8)*

Yield 55%; White solid; mp 122-125°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.73-2.27 (m, 47H, CH, CH$_2$), 0.73 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.85 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.68 (s, 3H, CH$_3$), 2.38 (t, *J* = 6.5 Hz, 2H, CH$_2$), 2.58 (t, *J* = 6.3 Hz, 2H, CH$_2$), 2.90-3.03 (m, 3H, H-19, CH$_2$), 3.30 (td, *J* = 7.2 Hz, 5.3 Hz, 2H, CH$_2$), 3.64 (ddd, *J* = 12.1 Hz, 9.8 Hz, 4.3 Hz, 1H, H-3), 4.59 (brs, 1H, H-29), 4.72 (brs, 1H, H-29), 5.57 (d, *J* = 9.9 Hz, 1H, NH), 12.57 (br s, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 14.8, 16.2, 16.6, 18.7, 19.5, 19.9, 20.9, 22.7, 24.9, 25.6, 25.8, 26.0, 27.0, 27.2, 28.5, 29.0, 29.1, 29.5, 29.8, 30.7, 31.7, 32.3, 34.4, 37.1, 37.2, 37.9, 38.5, 38.6, 39.3, 40.8, 42.6, 43.5, 43.9, 47.1, 49.4, 50.6, 56.1, 56.4, 56.5, 108.7, 109.8, 150.6, 173.0, 173.1, 181.2, 194.9, 204.0. HR-MS (ESI): m/z calcd for $C_{50}H_{80}N_2NaO_5$ [M+Na]$^+$ 811.5965; found 811.5996.

2.1.1.9. *3-Deoxy-3β-((7-(4,4-dimethyl-2-heptylamino-6-oxocyclohex-1-enyl)-7-oxoheptanamido)) betulinic Acid (9)*

Yield 50%; White solid; mp 127-130°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.73-2.27 (s, 45H, CH, CH$_2$), 0.73 (s, 3H, CH$_3$), 0.80 (s, 3H, CH$_3$), 0.85 (s, 3H, CH$_3$), 0.92 (s, 3H, CH$_3$), 0.96 (s, 3H, CH$_3$), 1.05 (s, 6H, 2CH$_3$), 1.68 (s, 3H, CH$_3$), 2.26 (s, 2H, CH$_2$), 2.88-3.02 (m, 3H, CH$_2$, H-19), 3.30 (td, *J* =7.1, 5.2 Hz, 2H, CH$_2$), 3.64 (ddd, *J* =12.3, 9.9, 4.3 Hz, 1H, H-3), 4.60 (brs, 1H, H-29), 4.73 (brs, 1H, H-29), 5.56 (d, 1H, *J* = 9.8 Hz, NH), 12.68 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 14.3, 14.8, 16.2, 16.6, 18.7, 19.5, 20.9, 22.7, 24.9, 25.6, 25.8, 26.0, 27.0, 28.5, 28.6, 29.0, 29.1, 29.6, 29.8, 30.7, 31.7, 32.3, 34.4, 37.1, 37.2, 37.9, 38.5, 39.3, 40.6, 40.8, 42.6, 43.5, 43.9, 47.1, 49.4, 50.6, 52.2, 56.1, 56.4, 56.5, 107.5, 109.8, 150.6, 172.0, 173.2, 181.2, 194.5, 203.6. HR-MS (ESI): m/z calcd for $C_{52}H_{84}N_2NaO_5$ [M+Na]$^+$ 839.6278; found 839.6305.

2.1.2. *Synthesis of 3β-amino-3-deoxybetulinic Acid (10)*

To a solution of betulonic acid (1.36 g, 3 mmol) in dry methanol, ammonium acetate (2.22 g, 30 mmol) and cyanoborohydride (0.19 g, 3 mmol) were added. After stirring at room temperature for 12 hr, methanol was evaporated under reduced pressure. To the residue, water (100 ml) was added and the pH of aqueous layer was adjusted to 9 using 1M sodium hydroxide. The precipitate was filtered and purified by silica gel column chromatography using a mixture of chloroform:petroleum as an eluent at a ratio of 20:1 to 10:1 to afford 0.68 g (50% yield) of 3β-amino-3-deoxybetulinic acid (**10**) as white solid; mp 271-274°C. ^{1}H NMR (500 MHz, CD$_3$COOD) δ: 1.00-2.57 (m, 22H, CH, CH$_2$), 1.13 (s, 3H, CH$_3$), 1.15 (s, 3H, CH$_3$), 1.23 (s, 3H, CH$_3$), 1.28 (s, 3H, CH$_3$), 1.31 (s, 3H, CH$_3$), 1.96 (s, 3H, CH$_3$), 3.24-3.30 (m, 2H, H-3, H-19), 4.87 (brs, 1H, H-29), 5.00 (brs, 1H, H-29). ^{13}C NMR (125 MHz, CD$_3$COOD) δ: 15.1, 16.1, 16.3, 16.5, 19.1, 21.7, 24.0, 26.5, 28.1, 30.6, 31.4, 32.9, 35.1, 37.4, 37.9, 38.0, 39.1, 39.4, 41.6, 43.4, 48.1, 50.1, 51.4, 56.6, 57.4, 61.6, 110.5, 151.4, 183.1. Anal. Calcd for $C_{30}H_{49}NO_2$: C, 79.07; H, 10.84; N, 3.07. Found: C, 79.15; H, 10.91; N, 3.12.

2.1.3. Synthesis of 7-aza- and 13-azaprostanoic Acids 11-19

To a solution of compound **32-37, 44-46** (1 mmol) in the mixture of tetrahydrofuran (THF) (5 ml) and H_2O (2 ml), sodium hydroxide (2 mmol) was added. After stirring at room temperature for 2 hr, THF was evaporated under reduced pressure. To the residue, 3% HCl (30 ml) was added and the resulting mixture was extracted with chloroform (3 x 10 ml). Combined organic layers were dried (anhydrous Na_2SO_4), and the solvent was evaporated under reduced pressure to give the desired acids **11-19**.

2.1.3.1. 6-((2-Heptanoyl-3-oxocyclopent-1-en-1-yl)amino)hexanoic Acid (11)

Yield 95%; White solid; mp 61-63°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.84 (t, 3H, CH$_3$), 1.18-1.71 (m, 14H, 7CH$_2$), 2.35 (t, J = 7.3 Hz, 2H, CH$_2$), 2.44-2.47 (m, 2H, CH$_2$), 2.64-2.66 (m, 2H, CH$_2$), 2.87 (t, J = 7.5 Hz, 2H, CH$_2$), 3.35 (q, J = 6.7 Hz, 2H, CH$_2$), 10.40 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 22.6, 24.3, 26.2, 29.2, 29.4, 30.4, 31.8, 33.5, 33.8, 40.6, 44.0, 110.3, 177.8, 182.0, 200.4, 200.5. Anal. Calcd for C$_{18}$H$_{29}$NO$_4$: C, 66.84; H, 9.04; N, 4.33. Found: C, 66.93; H, 9.16; N, 4.39.

2.1.3.2. 6-((2-Heptanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanoic Acid (12)

Yield 98%; Colorless oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.86 (t, J = 7.0 Hz, 3H, CH$_3$), 1.25-1.35 (m, 6H, 3CH$_2$), 1.43-1.49 (m, 2H, CH$_2$), 1.52-1.58 (m, 2H, CH$_2$), 1.65-1.73 (m, 4H, 2CH$_2$), 1.88-1.93 (m, 2H, CH$_2$), 2.37 (t, J = 7.3 Hz, 2H, CH$_2$), 2.44 (t, J = 6.5 Hz, 2H, CH$_2$), 2.58 (t, J = 6.3 Hz, 2H, CH$_2$), 2.92-2.95 (m, 2H, CH$_2$), 3.34 (td, J = 7.1 Hz, 5.3 Hz, 2H, CH$_2$), 12.61 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 19.8, 22.7, 24.3, 25.3, 26.4, 27.2, 29.1, 29.4, 31.9, 33.8, 38.1, 43.6, 44.0, 108.7, 173.3, 178.1, 195.3, 204.6. Anal. Calcd for C$_{19}$H$_{31}$NO$_4$: C, 67.63; H, 9.26; N, 4.15. Found: C, 67.71; H, 9.32; N, 4.19.

2.1.3.3. 6-((2-Heptanoyl-5,5-dimethyl-3-oxocyclohex-1-en-1-yl)amino)hexanoic Acid (13)

Yield 95%; White solid; mp 42-44°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.85 (t, J = 6.9 Hz, 3H, CH$_3$), 1.05 (s, 6H, 2CH$_3$), 1.24-1.35 (m, 6H, 3CH$_2$-

3), 1.44-1.58 (m, 4H, 2CH$_2$), 1.65-1.73 (m, 4H, 2CH$_2$), 2.30 (s, 2H, CH$_2$), 2.37 (t, J = 7.3 Hz, 2H, CH$_2$), 2.42 (s, 2H, CH$_2$), 2.93-2.96 (m, 2H, CH$_2$), 3.33 (td, J = 7.0 Hz, 5.3 Hz, 2H, CH$_2$), 12.71 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 22.8, 24.3, 25.4, 26.4, 28.4, 29.2, 29.4, 30.7, 31.9, 33.8, 40.6, 43.6, 43.9, 51.9, 107.6, 172.2, 178.2, 194.8, 204.1. Anal. Calcd for C$_{21}$H$_{35}$NO$_4$: C, 69.01; H, 9.65; N, 3.83. Found: C, 68.93; H, 9.56; N, 3.80.

2.1.3.4. 6-((2-Octanoyl-3-oxocyclopent-1-en-1-yl)amino)hexanoic Acid (14)

Yield 98%; White solid; mp 47-50°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.85 (t, J = 6.9 Hz, 3H, CH$_3$), 1.19-1.34 (m, 8H, 4CH$_2$), 1.41-1.47 (m, 2H, CH$_2$), 1.52-1.58 (m, 2H, CH$_2$), 1.64-1.71 (m, 4H, CH$_2$), 2.36 (t, J = 7.3 Hz, 2H, CH$_2$), 2.45-2.48 (m, 2H, CH$_2$), 2.64-2.67 (m, 2H, CH$_2$), 2.88 (t, J = 7.5 Hz, 2H, CH$_2$), 3.36 (q, J = 6.8 Hz, 2H, CH$_2$), 10.41 (t, J = 6.1 Hz, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 22.8, 24.3, 24.4, 26.2, 29.3, 29.4, 29.5, 31.9, 33.5, 33.8, 40.6, 44.0, 110.4, 178.0, 182.0, 200.4, 200.6. Anal. Calcd for C$_{19}$H$_{31}$NO$_4$: C, 67.63; H, 9.26; N, 4.15. Found: C, 67.55; H, 9.19; N, 4.11.

2.1.3.5. 6-((2-Octanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanoic Acid (15)

Yield 93%; Colorless oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.85 (t, J = 6.9 Hz, 3H, CH$_3$), 1.20-1.34 (m, 8H, 4CH$_2$), 1.42-1.49 (m, 2H, CH$_2$), 1.52-1.58 (m, 2H, CH$_2$), 1.64-1.72 (m, 4H, 2CH$_2$), 1.87-1.92 (m, 2H, CH$_2$), 2.36 (t, J = 7.4 Hz, 2H, CH$_2$), 2.41 (t, J = 6.5 Hz, 2H, CH$_2$), 2.57 (t, 2H, J = 6.2 Hz, CH$_2$), 2.91-2.94 (m, 2H, CH$_2$), 3.31-3.35 (m, 2H, CH$_2$), 12.59 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 19.8, 22.8, 24.3, 25.4, 26.4, 27.1, 29.1, 29.4, 29.7, 31.9, 33.8, 38.3, 43.5, 43.9, 108.8, 173.1, 178.0, 195.3, 204.5. Anal. Calcd for C$_{20}$H$_{33}$NO$_4$: C, 68.34; H, 9.46; N, 3.99. Found: C, 68.46; H, 9.51; N, 4.02.

2.1.3.6. 6-((5,5-Dimethyl-2-octanoyl-3-oxocyclohex-1-en-1-yl)amino)hexanoic Acid (16)

Yield 98%; Colorless oil. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.85 (t, J = 6.9 Hz, 3H, CH$_3$), 1.05 (s, 6H, CH$_3$), 1.22-1.35 (m, 8H, 4CH$_2$), 1.43-1.49 (m, 2H, CH$_2$), 1.52-1.58 (m, 2H, CH$_2$), 1.65-1.73 (m,

4H, 2CH$_2$), 2.30 (s, 2H, CH$_2$), 2.37 (t, *J* = 7.3 Hz, 2H, CH$_2$), 2.42 (s, 2H, CH$_2$), 2.93-2.96 (m, 2H, CH$_2$), 3.31-3.35 (m, 2H, CH$_2$), 12.71 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.2, 22.8, 24.3, 25.4, 26.4, 28.4, 29.2, 29.4, 29.7, 30.7, 32.0, 33.8, 40.6, 43.6, 43.9, 51.9, 107.6, 172.2, 178.2, 194.7, 204.1. Anal. Calcd for C$_{22}$H$_{37}$NO$_4$: C, 69.62; H, 9.83; N, 3.69. Found: C, 69.75; H, 9.87; N, 3.71.

2.1.3.7. *7-(2-(Heptylamino)-5-oxocyclopent-1-en-1-yl)-7-oxoheptanoic Acid (17)*

Yield 95%; White solid; mp 76-78°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.87 (t, *J* = 6.8 Hz, 3H, CH$_3$), 1.23-1.42 (m, 10H, 5CH$_2$), 1.57-1.68 (m, 6H, 3CH$_3$), 2.33 (t, *J* = 7.6 Hz, 2H, CH$_2$), 2.43-2.45 (m, 2H, CH$_2$), 2.64-2.66 (m, 2H, CH$_2$), 2.90 (t, *J* = 7.4 Hz, 2H, CH$_2$), 3.33 (q, *J* = 6.8 Hz, 2H, CH$_2$), 10.36 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.1, 22.7, 24.0, 24.2, 24.8, 26.8, 28.9, 29.8, 31.7, 33.6, 34.1, 40.3, 44.3, 110.3, 178.7, 181.8, 200.0, 200.2. Anal. Calcd for C$_{19}$H$_{31}$NO$_4$: C, 67.63; H, 9.26; N, 4.15. Found: C, 67.54; H, 9.20; N, 4.11.

2.1.3.8. *7-(2-(Heptylamino)-6-oxocyclohex-1-en-1-yl)-7-oxoheptanoic Acid (18)*

Yield 95%; White solid; mp 84-86°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.87 (t, *J* = 6.6 Hz, 3H, CH$_3$), 1.22-1.44 (m, 10H, 5CH$_2$), 1.56-1.69 (m, 6H, 3CH$_2$), 1.90 (q, *J* = 6.5 Hz, 2H, CH$_2$), 2.33 (t, *J* = 7.6 Hz, 2H, CH$_2$), 2.39 (t, 2H, *J* = 6.5 Hz, 2H, CH$_2$), 2.92-2.95 (m, 2H, CH$_2$), 3.30 (q, *J* = 6.8 Hz, 2H, CH$_2$), 12.55 (brs, 1H, NH). ^{13}C NMR (125 MHz, CDCl$_3$) δ: 14.1, 19.8, 22.7, 24.8, 24.9, 27.0, 27.1, 28.9, 29.1, 29.4, 31.7, 34.2, 38.4, 43.5, 43.8, 108.7, 173.1, 179.0, 195.3, 204.0. Anal. Calcd for C$_{20}$H$_{33}$NO$_4$: C, 68.34; H, 9.46; N, 3.99. Found: C, 68.45; H, 9.52; N, 4.03.

2.1.3.9. *7-(2-(Heptylamino)-4,4-dimethyl-6-oxo-cyclohex-1-en-1-yl)-7-oxoheptanoic Acid (19)*

Yield 95%; White solid; mp 65-67°C. ^{1}H NMR (500 MHz, CDCl$_3$) δ: 0.87 (t, *J* = 6.7 Hz, 3H, CH$_3$), 1.04 (s, 6H, 2CH$_3$), 1.22-1.44 (m, 10H, 5CH$_2$), 1.55-1.69 (m, 6H, 3CH$_2$), 2.27 (s, 2H, CH$_2$), 2.33 (t, *J* = 7.6 Hz, 2H, CH$_2$), 2.41 (s, 2H, CH$_2$), 3.04-2.88 (m, 2H, CH$_2$), 3.30 (td, *J* = 7.1 Hz, 5.3 Hz, 2H, CH$_2$), 12.66 (t, *J* = 5.4 Hz, 1H, NH). ^{13}C NMR (126 MHz, CDCl$_3$) δ: 14.1, 22.7,

24.8, 24.9, 26.9, 28.4, 28.9, 29.1, 29.5, 30.7, 31.7, 34.2, 40.5, 43.5, 43.9, 52.0, 107.5, 172.1, 178.9, 194.8, 203.5. Anal. Calcd for C$_{22}$H$_{37}$NO$_4$: C, 69.62; H, 9.83; N, 3.69. Found: C, 69.53; H, 9.79; N, 3.65.

2.2. Pharmacological Activity

2.2.1. *Animals*

The pharmacological studies were carried out on outbred albino male mice or C57BL/6 female mice weighing 20-25 g with eight animals in each group. All the animals were taken from SPF-vivarium of the Institute of Cytology and Genetics of the Siberian Branch of Russian Academy of Sciences. Mice were housed in wire cages at 22-25°C on a 12 hr light-dark cycle. The animals had free access to standard pellet diet, tap water was available ad libitum. All the experimental procedures were approved by the Bio-Ethical Committee of the N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the Siberian Branch of Russian Academy of Sciences in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and the requirements and recommendations of the Guide for the Care and Use of Laboratory Animals.

2.2.2. *In vivo Anti-inflammatory Activity*

The anti-inflammatory activity of hybrids **1-9**, aminobetulinic acid **10** and azaprostanoic acid **17** was evaluated in three acute inflammation models - the histamine-induced, the formalin-induced and concanavalin A-induced mouse paw edema. In accordance to the model, 0.05 mL of 0.1% histamine dihydrochloride solution or 3% formalin solution or 0.02 ml of 0.5% concanavalin A solution was injected into the aponeurosis of the mouse hind paw. The test compounds **1-9** were dissolved in saline containing 0.5% Tween 80 just before the use and were administered at the dose of 20 mg/kg 1 hr before histamine, formalin or concanavalin A injection. In concanavalin A-induced edema model, test compounds were administered twice 24 hr and 1 hr before phlogogen. The reference agent indomethacin (Fluka) was administered in the same manner and in the same dose as test substances. The control group of animals received an equivalent volume of water-tween mixture. Ani-

mals were sacrificed by cervical dislocation under the light ether anesthesia 5 hr after injection of the phlogogenic agent (histamine or formalin) or 1 hr after the last concanavalin A injection. The mouse paws were cut off at the ankle joint and weighed. The ratio of the difference in weight between the treated and untreated hind paws to the weight of the untreated hind paw was used as an inflammatory edema index (IEI).

2.2.3. Antinociceptive Evaluation

The antinociceptive activity of hybrids **1-9,** aminobetulinic acid **10** and azaprostanoic acid **17** was evaluated in two standard experimental pain models - the acetic acid-induced abdominal writhing and the hot-plate test. The test compounds dissolved in saline containing 0.5% Tween 80 were administered i.p. at a dose of 20 mg/kg 1 hr before testing. Indomethacin at a dose of 20 mg/kg was used as a reference drug. In the acetic acid-induced writhing test, the pain reaction was determined by the number of abdominal convulsions recorded during 3 min after 5 min of 0.75% acetic acid injection (0.1 mL/10 g body weight i.p.) [30]. The percentage of pain reaction inhibition was calculated according to the following equation: % inhibition = 100 × (A - B)/A, where A was the mean number of writhes in the control group, and B was the mean number of writhes in the test group. In the hot-plate test, animals were placed individually on the hot metallic plate which was heated to a constant temperature 53 ± 0.5°C and surrounded by acrylic cage. The latency to respond was observed with hind paw licking, flick or jumping and the time of response was recorded using a stopwatch [31].

2.2.4. Cytotoxicity Assay

DMEM with 10% fetal bovine serum (Gibco, United States) was used for culturing. Optical density was measured on a Multiskan RC spectrophotometer (LabSystems). The MTT test was carried out according to the standard procedure [32] using the reagent 3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-yltetrazolium bromide (MTT, Sigma, United States). Cell lines were obtained from the American Type Culture Collection: U-87 MG (ATCC number HBT-14), MCF7 (ATCC number HTB-22). Immortalized human fibroblasts used as

a negative control were provided by A. Schilov (Institute of Cytology and Genetics of Siberian Branch of Russian Academy of Sciences, Novosibirsk, Russia). The viability for DMSO (negative control) was calculated as 100%. All culture experiments were carried out independently three times with two repeats in the experiment, and the final result is presented as concentration, which caused 50% inhibition of cell population growth ($IC_{50} \pm$ SEM).

2.2.5. Statistical Analysis

Data was represented as mean ± standard error (SEM) from the groups of animals. The statistical analysis was applied with parametric and nonparametric methods using "STATISTICA 6" software. The differences were significant at $P < 0.05$.

## 3. RESULTS AND DISCUSSION

3.1. Chemistry

The synthesis of the desired betulinic acid-azaprostanoid hybrids **1-9** with amide linker was accomplished as outlined in Scheme **1**.

As a starting compound for the synthesis of hybrids **1-9**, we took naturally accessible lupane triterpenoid betulin [33]. Betulin was converted into betulonic acid by using Jones' oxidation according to a published procedure [34]. Reductive amination of betulonic acid under an action of cyanoborohydride in the presence of ammonium acetate in dry methanol resulted in a mixture of β- and α-isomers [35]. Target 3β-amino-3-deoxybetulinic acid (**10**) was isolated by us using silica gel column chromatography of the mixture in a yield of 50%. Triterpenoid hybrids **1-9** were synthesized *via* the condensation of prepared aminobetulinic acid **10** with 7-azaprostanoic acids **11-16** or 13-azaprostanoic acids **17-19** under an action of *N,N'*-dicyclohexylcarbodiimide (DCC) in the presence of 4-dimethylaminopyridine (DMAP) in methylene chloride in yields of 54-65%.

Azaprostanoic acids and their homo analogues **11-19** were prepared on the basis of cyclic β-triketones with 2-alkanoyl or 2-(ω-alkoxycarbonylalkanoyl) side chains under known methods (Scheme **2**) [22]. A treatment of 2-heptanoyl- or 2-octanoylcycloalkane-1,3-diones **20-25** with oxalyl

Scheme 1. A synthetic route for the preparation of hybirds **1-9**.

Cmpd	Z	n	Cmpd	Z
11, 20, 26, 32	CH_2	1	**17, 38, 41, 44**	CH_2
12, 21, 27, 33	$(CH_2)_2$	1	**18, 39, 42, 45**	$(CH_2)_2$
13, 22, 28, 34	$CH_2C(CH_3)_2$	1	**19, 40, 43, 46**	$CH_2C(CH_3)_2$
14, 23, 29, 35	CH_2	2		
15, 24, 30, 36	$(CH_2)_2$	2		
16, 25, 31, 37	$CH_2C(CH_3)_2$	2		

Scheme 2. Synthesis of azaprostanoic acids **11-19**.

chloride gave the vinylogous chlorides **26-31**. An interaction of the latter with methyl-ε-aminohexanoate hydrochloride in methanol led to 7-azaprostanoids **32-37**. 13-Azaprostanoids **44-46** were synthesized *via* the transformation of 2-(ω-ethoxycarbonylalkanoyl)cycloalkane-1,3-diones **38-40** under an action of oxalyl chloride into the vinylogous chlorides **41-43** followed by the treatment of the latter with a twofold excess of heptylamine in chloroform. The obtained azaprostanoids **32-37, 44-46** were hydrolyzed with sodium hydroxide in THF/H_2O to give the acids **11-19** in 93-98% yields.

All the target compounds have not been previously reported in the literature, and the structures were identified by physicochemical and spectral means, and both the analytical and spectral data of the synthesized compounds were totally consistent with their molecular structures.

3.2. Pharmacology

The anti-inflammatory and analgesic activities of hybrids **1-9**, 3β-amino-3-deoxybetulinic acid (**10**) and 13-aza-7,9-dioxo-8(12)prostenoic acid (**17**) were investigated *in vivo* in comparison with indomethacin. Three models of mouse paw in-

Table 1.   The influence of compounds 1-10, 17 on mice paw edema indexes in three models of inflammation.

Agent	Dose, mg/kg	Mean Indexes of Paw Edema, %		
		Histamine-Induced Edema	Formalin-Induced Edema	Concanavalin A-Induced Edema
Control	-	25.27 ± 8.69	71.58 ± 7.78	24.93 ± 2.14
1	20	19.83 ± 5.55	70.17 ± 4.85	$14.77 \pm 2,99$***
2	20	23.76 ± 7.48	69.78 ± 10.82	18.76 ± 2.88***
3	20	26.67 ± 10.89	72.33 ± 6.61	$21.88 \pm 4.25^{\#}$
4	20	27.15 ± 9.43	71.47 ± 18.77	18.44 ± 4.65**
5	20	21.99 ± 4.64	75.02 ± 12.88	18.59 ± 5.79*
6	20	24.98 ± 5.46	72.87 ± 8.28	18.12 ± 4.52**
7	20	19.92 ± 4.25	84.19 ± 8.85	$24.57 \pm 6.81^{\#}$
8	20	20.24 ± 4.05	73.71 ± 18.41	$21.96 \pm 4.73^{\#}$
9	20	22.37 ± 8.70	74.14 ± 17.32	17.25 ± 3.79***
10	20	22.27 ± 5.22	73.90 ± 17.34	16.42 ± 3.23***
17	20	17.88 ± 4.91	71.02 ± 18.66	21.44 ± 3.9*$^{\#}$
Indo-methacin	20	16.86 ± 3.31*	48.02 ± 5.00*	17.07 ± 2.70***

*$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$- difference with control are significant.
$^{\#}P \leq 0.05$- difference with indomethacin are significant.

flammatory edema induced by histamine, formalin or concanavalin A injection were used (Table **1**). In the first two models of the exudative inflammation, none of the compounds at dose 20 mg/kg i.p. displayed a statistically significant effect. In the immunogenic (concanavalin A-induced) inflammation model, the betulinic acid-7-azaprostanoid hybrids **1**, **2**, **4-6** displayed a statistically significant effect by lowering the edema index 1.3-1.7 times relative to the control group. Among the hybrids with 13-azaprostanoids **7-9**, only hybrid **9** exhibited a statistically significant effect by lowering the edema index 1.4 times relative to the control group (Table **1**).

It is noteworthy that the aforementioned hybrids have anti-inflammatory activity, which is comparable to that of indomethacin in the immunogenic inflammation model, whereas in the exudative inflammation models, the activity of those substances was lower to that of indomethacin. The inflammatory response induced by histamine or formalin injection is mediated mainly through the activation of endothelial secretion of the pro-

inflammatory and nociceptive (pain-generative) mediators as histamine, serotonin, bradykinin, calcitonin. They increase the excitation of primary afferent neurons and vascular leakage resulted in local edema and neutrophil infiltration [36]. Lectin concanavalin A injection causes the macrophage and mast cell activation and degranulation resulted in allergic-like reaction and edema. Obviously, the anti-inflammatory effect of hybrid agents is provided by their interactions mainly with the cells involved in inflammatory/immunogenic processes. In this case, the triterpenoid structure contributes significantly to this effect as it has been shown that the aminobetulinic acid **10** decreased allergic-like edema more potently compared to 13-azaprostanoic acid **17** (respectively 1.5 times versus 1.2 times relative to the control group) (Table **1**).

Antinociceptive properties of compounds **1-10**, **17** were investigated using models of visceral and tactile pain. In the visceral pain model induced by intraperitoneal injection of 0.75% acetic acid, hybrids **1-9** displayed an analgesic effect ranging from weak to moderate (Table **2**). Hybrids with

Table 2. Analgesic activity of compounds 1-10, 17.

Agent	Dose, mg/kg	A Pain Reaction of Mice in Visceral and Tactile Pain Models	
		Model of Visceral Pain, Number of Writhes During 3 Minutes	Model of Tactile Pain, Time Until Licking of the Hind Paw, Sec
Control	-	16.63 ± 3,70	6.63 ± 1.84
1	20	14.88 ± 6,85	6.25 ± 1.28
2	20	14.63 ± 5,42	5.63 ± 0.74
3	20	13.75 ± 3,42	5.63 ± 1.30
4	20	13.38 ± 6,12*	7.00 ± 1,77
5	20	13.63 ± 3,66*	5.38 ± 1.77
6	20	12.38 ± 2.67*	6.38 ± 1.06
7	20	10.50 ± 2.33*	7.75 ± 2.43
8	20	13.63 ± 2.77*	7.00 ± 1.60
9	20	7.63 ± 3.44**	6.25 ± 1.16
10	20	9.75 ± 2.12**	5.25 ± 0.89
17	20	15.00 ± 3.51	6.50 ± 1.51
Indomethacin	20	4.25 ± 1.83***	7.50 ± 1.85

*$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.001$ - difference with control are significant.

13-azaprostanoids **7-9** displayed more significant analgesic action by lowering the number of writhes 1.2-2.2 times relative to the control group, whereas the similar effect of hybrids with 7-azaprostanoids **1-6** did not exceed 1.3 times relative to the control group. Hybrid **9** and amino acid **10** were the most active among the tested compounds and had an activity lower to that of indomethacin 1.8 and 2.3 times, respectively. The results indicated that the antinociceptive effect of hybrids was due to their triterpenoid structure while azaprostanoic acid hadn't visible activity. In the tactile pain model induced by heating, no significant differences in pain threshold in the investigated groups *versus* control were found.

The cytotoxic activity of the synthesized hybrids **1-9** was evaluated *in vitro* by the MTT assay on immortalized human fibroblasts, human breast cancer (MCF7) and human glioblastoma cell lines (U-87 MG) using doxorubicin, 3β-amino-3-deoxy-betulinic acid (**10**) and 13-aza-7,9-dioxo-8(12) prostenoic acid (**17**) as reference compounds (Table **3**).

All the hybrids exhibited much lower cytotoxicity than doxorubicin, aminobetulinic acid **10** and

13-azaprostanoic acid **17** (last in case of U-87 MG). Some agents were more toxic than azaprostanoid **17**: hybrids **2**, **6** in MCF7 cell line and hybrids **3**, **8** in immortalized fibroblasts.

CONCLUSION

In summary, in the current work, we developed a simple synthesis of novel betulinic acid-azaprostanoid hybrids containing amide linkage. The synthetic pathway includes the transformation of betulin *via* Jones' oxidation into betulonic acid, reductive amination of the latter and coupling obtained by 3β-amino-3-deoxybetulinic acid with the appropriate 7- or 13-azaprostanoic acids and their homo analogues. The synthesized hybrids **1-9** were evaluated for *in vivo* anti-inflammatory activity using mouse paw edema models induced by the histamine, formalin and concanavalin A. In the immunogenic inflammation model, most of the synthesized compounds showed pronounced anti-inflammatory effect at 20 mg/kg, which was comparable to that of indomethacin. Compound **1** showed the most potent inhibitory effect towards immunogenic inflammation among all hybrids and their precursors - 3β-amino-3-deoxybetulinic acid

Table 3.   **Concentrations of half-maximal inhibition (IC_{50}) of compounds 1-10, 17 on U-87 MG, MCF7 cell lines and immortalized human fibroblasts.**

Compound	$IC_{50} \pm$ SEM, µM		
	U-87 MG	**MCF7**	**Immortalized Human Fibroblasts**
Doxorubicin	4.02 ± 1.17	5.51 ± 1.74	5.74 ± 2.04
1	> 100	98.71 ± 10.02	> 100
2	> 100	41.4 ± 7.88	84.26 ± 11.08
3	> 100	> 100	51.19 ± 7.44
4	70.36 ± 10.12	> 100	82.16 ± 10.52
5	66.6 ± 9.84	> 100	> 100
6	31.75 ± 4.87	17.96 ± 4.54	> 100
7	74.7 ± 9.08	> 100	78.64 ± 10.11
8	38.53 ± 6.78	> 100	32.78 ± 5.61
9	59.92 ± 8.09	> 100	78.43 ± 9.88
10	< 10	< 10	< 10
17	8.28 ± 2.11	70.36 ± 5.96	61.27 ± 3.76

(**10**) and azaprostanoic acid **17**. In the visceral pain model, the hybrids **1**-**9** displayed analgesic effects ranged from weak to moderate which were less than that of indomethacin. The *in vitro* cytotoxicity study of the synthesized hybrids on cancer (MCF7, U-87MG) and non-cancer humane cell lines indicated that the hybridization of betulinic acid with azaprostanoids enhanced viability of the tested cells. Thus, the principal pharmacological effect of hybrids is the anti-inflammatory activity, substantially provided with the triterpenoid scaffold and in some cases, with the azaprostanoid scaffold, but the latter makes a significant contribution to reducing the toxicity of hybrids. These findings also showed the potential of molecular hybridization methods in the development of structurally new and safe anti-inflammatory agents. The hybrid **1** is suggested for further trials as a low toxic anti-inflammatory agent against immune-mediated inflammatory diseases.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

HUMAN AND ANIMAL RIGHTS

No humans were used in the study that is the basis of this research. All the experimental protocols on animals were in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes, and the requirements (European Communities Council Directives of 24 November 1986, 86/609/EEC) and recommendations of the Guide for the Care and Use of Laboratory Animals.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

Not applicable.

FUNDING

001) and Siberian Branch of the Russian Academy of Sciences (project 0302-2015-0003).

SUPPLEMENTARY MATERIAL

Supplementary material is available on the publisher's website along with the published article.

REFERENCES

[1]   Sun, L.D.; Wang, F.; Dai, F.; Wang, Y.H.; Lin, D.; Zhou, B. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent. *Biochem. Pharmacol.,* **2015**, *95*(3), 156-169.
http://dx.doi.org/10.1016/j.bcp.2015.03.014
PMID: 25850000

[2]   Dinarello, C.A. Anti-inflammatory agents: present and future. *Cell,* **2010**, *140*(6), 935-950.
http://dx.doi.org/10.1016/j.cell.2010.02.043
PMID: 20303881

[3]   Azab, A.; Nassar, A.; Azab, A.N. Anti-inflammatory activity of natural products. *Molecules,* **2016**, *21*(10), 1321.
http://dx.doi.org/10.3390/molecules21101321 PMID: 27706084

[4]   Newman, D.J.; Cragg, C.M. Natural product scaffolds of value in medicinal chemistry. *Privileged scaffolds in medicinal chemistry. Design, synthesis, evaluation*; Bräse, S., Ed.; Royal Society of Chemistry: Cambridge, UK, **2016**, pp. 348-378.

[5]   Tolstikova, T.G.; Sorokina, I.V.; Tolstikov, G.A.; Tolstikov, A.G.; Flekhter, O.B. Biological activity and pharmacological prospects of lupane terpenoids: I. Natural lupane derivatives. *Bioorg. Khim.,* **2006**, *32*(1), 42-55.
PMID: 16523720

[6]   Xu, G.B.; Xiao, Y.H.; Zhang, Q.Y.; Zhou, M.; Liao, S.G. Hepatoprotective natural triterpenoids. *Eur. J. Med. Chem.,* **2018**, *145*, 691-716.
http://dx.doi.org/10.1016/j.ejmech.2018.01.011
PMID: 29353722

[7]   Jonnalagadda, S.C.; Suman, P.; Morgan, D.C.; Seay, J.N. Recent developments on the synthesis and applications of betulin and betulinic acid derivatives as therapeutic agents. In: *Studies in Natural Products Chemistry*; Atta-ur-, Rahman., Ed.; Elsevier: Amsterdam,, **2017**, pp. 45-84.

http://dx.doi.org/10.1016/B978-0-444-63930-1.00002-8

[8]   Ríos, J.L. Effects of triterpenes on the immune system. *J. Ethnopharmacol.,* **2010**, *128*(1), 1-14.
http://dx.doi.org/10.1016/j.jep.2009.12.045
PMID: 20079412

[9]   Cichewicz, R.H.; Kouzi, S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. *Med. Res. Rev.,* **2004**, *24*(1), 90-114.
http://dx.doi.org/10.1002/med.10053
PMID: 14595673

[10]   Lingaraju, M.C.; Pathak, N.N.; Begum, J.; Balaganur, V.; Ramachandra, H.D.; Bhat, R.A.; Ram, M.; Singh, V.; Kandasamy, K.; Kumar, D.; Kumar, D.; Tandan, S.K. Betulinic acid attenuates renal oxidative stress and inflammation in experimental model of murine polymicrobial sepsis. *Eur. J. Pharm. Sci.,* **2015**, *70*, 12-21.
http://dx.doi.org/10.1016/j.ejps.2015.01.001
PMID: 25585354

[11]   Kim, K.S.; Lee, D.S.; Kim, D.C.; Yoon, C.S.; Ko, W.; Oh, H.; Kim, Y.C. Anti-inflammatory effects and mechanisms of action of coussaric and betulinic acids isolated from *Diospyros kaki* in lipopolysaccharide-stimulated RAW 264.7 macrophages. *Molecules,* **2016**, *21*(9), 1206.
http://dx.doi.org/10.3390/molecules21091206 PMID: 27618005

[12]   Costa, J.F.O.; Barbosa-Filho, J.M.; Maia, G.L.; Guimarães, E.T.; Meira, C.S.; Ribeiro-dos-Santos, R.; de Carvalho, L.C.P.; Soares, M.B.P. Potent anti-inflammatory activity of betulinic acid treatment in a model of lethal endotoxemia. *Int. Immunopharmacol.,* **2014**, *23*(2), 469-474.
http://dx.doi.org/10.1016/j.intimp.2014.09.021 PMID: 25281393

[13]   Yun, Y.; Han, S.; Park, E.; Yim, D.; Lee, S.; Lee, C.K.; Cho, K.; Kim, K. Immunomodulatory activity of betulinic acid by producing pro-inflammatory cytokines and activation of macrophages. *Arch. Pharm. Res.,* **2003**, *26*(12), 1087-1095.
http://dx.doi.org/10.1007/BF02994763
PMID: 14723345

[14]   Patlolla, J.M.R.; Rao, C.V. Triterpenoids for cancer prevention and treatment: current status and future prospects. *Curr. Pharm. Biotechnol.,* **2012**, *13*(1), 147-155.
http://dx.doi.org/10.2174/138920112798868719
PMID: 21466427

[15]   Smyth, E.M.; Grosser, T.; Wang, M.; Yu, Y.; Fitz-Gerald, G.A. Prostanoids in health and disease. *J. Lipid Res.,* **2009**, *50*(Suppl.), S423-S428.
http://dx.doi.org/10.1194/jlr.R800094-JLR200 PMID: 19095631

[16]   Sykes, L.; MacIntyre, D.A.; Teoh, T.G.; Bennett, P.R. Anti-inflammatory prostaglandins for the prevention of preterm labour. *Reproduction,* **2014**, *148*(2), R29-R40.

http://dx.doi.org/10.1530/REP-13-0587
PMID: 24890751

[17]   Gilroy, D.W.; Colville-Nash, P.R.; Willis, D.; Chivers, J.; Paul-Clark, M.J.; Willoughby, D.A. Inducible cyclooxygenase may have anti-inflammatory properties. *Nat. Med.,* **1999,** *5*(6), 698-701.
http://dx.doi.org/10.1038/9550 PMID: 10371510

[18]   Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature,* **1998,** *391*(6662), 79-82.
http://dx.doi.org/10.1038/34178 PMID: 9422508

[19]   Jiang, C.; Ting, A.T.; Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. *Nature,* **1998,** *391*(6662), 82-86.
http://dx.doi.org/10.1038/34184 PMID: 9422509

[20]   Rossi, A.; Kapahi, P.; Natoli, G.; Takahashi, T.; Chen, Y.; Karin, M.; Santoro, M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. *Nature,* **2000,** *403*(6765), 103-108.
http://dx.doi.org/10.1038/47520 PMID: 10638762

[21]   Lakhvich, F.A.; Pashkovskii, F.S.; Koroleva, E.V. Heteroprostanoids: synthesis and biological activity. *Russ. Chem. Rev.,* **1992,** *61*, 243-266.
http://dx.doi.org/10.1070/RC1992v061n02ABEH000943

[22]   Lakhvich, F.A.; Khlebnikova, T.S. Synthesis of 7-aza- and 13-azaprostanoids on the base of 2-acylcycloalkane-1,3-diones. *Vestsi Akad. Nav. BSSR, Ser. Khim. Nav,* **1989,** *4*, 39-45.

[23]   Kuz′mitskii, B.B.; Golubeva, M.B.; Mizulo, N.A.; Romanova, V.N.; Khlebnikova, T.S.; Lakhvich, F.A. Anti-ulcerative and anti-inflammatory activity of some 7-aza-13-keto- and 13-aza-7-ketoprostanoids. *Vestsi Akad. Nav. BSSR, Ser. Khim. Nav,* **1989,** *6*, 82-86.

[24]   Kuz′mitskii, B.B.; Ignat′eva, T.N.; Khlebnikova, T.S.; Lakhvich, F.A. Antiischemic and antiarrhythmic activity of some 7-aza- and 13-azaprostanoids. *Vestsi Akad. Nav. BSSR, Ser. Khim. Nav,* **1989,** *5*, 65-68.

[25]   Choudhary, S.; Singh, P.K.; Verma, H.; Singh, H.; Silakari, O. Success stories of natural product-based hybrid molecules for multi-factorial diseases. *Eur. J. Med. Chem.,* **2018,** *151*, 62-97.
http://dx.doi.org/10.1016/j.ejmech.2018.03.057
PMID: 29605809

[26]   Shaveta, M.; Mishra, S.; Singh, P. Hybrid molecules: the privileged scaffolds for various pharmaceuticals. *Eur. J. Med. Chem.,* **2016,** *124*, 500-536.
http://dx.doi.org/10.1016/j.ejmech.2016.08.039
PMID: 27598238

[27]   Khlebnicova, T.S.; Piven, Y.A.; Baranovsky, A.V.; Lakhvich, F.A.; Shishkina, S.V.; Zicāne, D.; Tetere, Z.; Rāviņa, I.; Kumpiņš, V.; Rijkure, I.; Mieriņa, I.; Peipiņš, U.; Turks, M. Synthesis of novel lupane triterpenoid-indazolone hybrids with oxime ester linkage. *Steroids,* **2017,** *117*, 77-89.
http://dx.doi.org/10.1016/j.steroids.2016.08.002
PMID: 27500691

[28]   Khlebnikova, T.S. Piven′, Y.A.; Lakhvich, F.A. Synthesis of new betulonic acid conjugates with 2-perfluoroacylcycloalkane-1,3-diones using polymethylenediamine linkers. *Chem. Nat. Compd.,* **2017,** *53*, 486-491.
http://dx.doi.org/10.1007/s10600-017-2028-x

[29]   Vasilevsky, S.F.; Govdi, A.I.; Shults, E.E.; Shakirov, M.M.; Sorokina, I.V.; Tolstikova, T.G.; Baev, D.S.; Tolstikov, G.A.; Alabugin, I.V. Efficient synthesis of the first betulonic acid-acetylene hybrids and their hepatoprotective and anti-inflammatory activity. *Bioorg. Med. Chem.,* **2009,** *17*(14), 5164-5169.
http://dx.doi.org/10.1016/j.bmc.2009.05.059   PMID: 19524443

[30]   Koster, R.; Anderson, M.; Deber, E.I. Acetic acid for analgetic screening. *Fed. Proc.,* **1959,** *18*, 412-414.

[31]   Eddy, N.B.; Leimbach, D. Studies of anesthetics. *J. Pharmacol. Exp. Ther.,* **1953,** *107*, 385-393.
PMID: 13035677

[32]   Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Methods,* **1983,** *65*(1-2), 55-63.
http://dx.doi.org/10.1016/0022-1759(83)90303-4
PMID: 6606682

[33]   Alakurtti, S.; Mäkelä, T.; Koskimies, S.; Yli-Kauhaluoma, J. Pharmacological properties of the ubiquitous natural product betulin. *Eur. J. Pharm. Sci.,* **2006,** *29*(1), 1-13.
http://dx.doi.org/10.1016/j.ejps.2006.04.006   PMID: 16716572

[34]   Kim, D.S.H.L.; Chen, Z.; van Tuyen, N.; Pezzuto, J.M.; Qiu, S.; Lu, Z.-Z. A concise semi-synthetic approach to betulinic acid from betulin. *Synth. Commun.,* **1997,** *27*, 1607-1612.
http://dx.doi.org/10.1080/00397919708006099

[35]   Kim, D.S.H.L.; Pezzuto, J.M.; Pisha, E. Synthesis of betulinic acid derivatives with activity against human melanoma. *Bioorg. Med. Chem. Lett.,* **1998,** *8*(13), 1707-1712.
http://dx.doi.org/10.1016/S0960-894X(98)00295-9
PMID: 9873420

[36]   Aman, R.; Schulidoi, R.; Lanz, I.; Donnerer, J. Hystamine-induced edema in the rat paw - effect of capcaicin denervation and a CGRP receptor antagonist. *Eur. J. Pharm,* **1995,** *279*, 227-231.
http://dx.doi.org/10.1016/0014-2999(95)00169-L